6th Annual Anti-Cancer Drug Discovery & Development Summit (CS300)

Venue: Radisson Plaza - Warwick Hotel Philadelphia

Location: Philadelphia, Pennsylvania, United States

Event Date/Time: Jul 21, 2004 End Date/Time: Jul 23, 2004
Registration Date: Jul 21, 2004
Early Registration Date: Jun 04, 2004
Report as Spam


As renewed hope for better success have emerged from the use of molecular biology to identify unique attributes of tumor cells that can be targeted as drug candidates, numerous agents are now in various stages of development. The finest group of oncology experts has been assembled at this meeting to address the most promising therapeutics including molecular targeted agents, antibodies, vascular targeting and more. Join high-level industrial cancer researchers and business development personnel worldwide at this widely attended conference.

Featured Presentations:

Cancer Therapy – A Proposal

Philip Frost, M.D., Ph.D.

Oncology Research, Wyeth

Approaches against Acquired Capabilities of Tumors & Iressa Update

Jeffrey H. Hanke, Ph.D.,

VP, Cancer Research, AstraZeneca R&D Boston

Discovery & Development Of Kinase Inhibitors For Cancer Treatment

Patrick M. O’Connor, Ph.D.

Vice President of Oncology/Diabetes/Obesity, Pfizer Global R&D

Mapping Molecular Networks: Protein Microarray Analysis of Human Cancer

Emanuel F. Petricoin, Ph.D.

Co-Director, NCI-FDA Clinical Proteomics Program

Senior Principal Investigator, OCGT/CBER/FDA

VEGF Trap: A Novel High-Affinity VEGF Blocker with Potent Anti-Tumor Effects

George D. Yancopoulos M.D., Ph.D.

President of the Laboratories & Chief Scientific Officer, Regeneron Pharmaceuticals, Inc.

Surrogate Markers to Determine Optimal Biologic Dose For Metronomic Chemotherapy and Other Antiangiogenic Drugs

Robert S. Kerbel, Ph.D.

Canada Research Chair in Molecular Medicine

Senior Scientist, Sunnybrook and Women's College Health Sciences Centre

Professor, Departments of Medical Biophysics, University of Toronto

Cancer Immunotherapy: Progress in Cancer Vaccine Development

Robert Hershberg, M.D., Ph.D.

SVP & Chief Medical Officer, Dendreon Corp.

For more information, visit: www.srinstitute.com/cs300.